Cartesian Therapeutics (RNAC) Revenue (2015 - 2026)
Cartesian Therapeutics (RNAC) posted quarterly Revenue of $78000.0 for Q1 2026, down 92.91% year-over-year from $1.1 million in Q1 2025, and down 91.76% quarter-over-quarter from $947000.0 in Q4 2025.
Cartesian Therapeutics (RNAC) Revenue (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has reported Revenue for 12 consecutive years, with $78000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Revenue fell 92.91% year-over-year to $78000.0; the TTM figure through Mar 2026 stood at $1.0 million (down 96.94% YoY), while the FY2025 annual figure was $2.8 million, down 92.69% from the prior year.
- Revenue fell to $78000.0 in Q1 2026 per RNAC's latest filing, from $947000.0 in the prior quarter.
- Across five years, Revenue topped out at $39.3 million in Q2 2022 and bottomed at -$836000.0 in Q4 2024.
- Historically, Revenue has averaged $12.7 million across 5 years, with a median of $6.2 million in 2023.
- On a YoY basis, Revenue climbed as much as 533.85% in 2024 and fell as far as 110.11% in 2024.
- Cartesian Therapeutics' Revenue stood at $16.8 million in 2022, then plunged by 50.78% to $8.3 million in 2023, then sank by 110.11% to -$836000.0 in 2024, then soared by 213.28% to $947000.0 in 2025, then slumped by 91.76% to $78000.0 in 2026.
- Business Quant data shows RNAC's Revenue at $78000.0 in Q1 2026, $947000.0 in Q4 2025, and $1.1 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Cartesian Therapeutics | 265.54 Mn | 265.54 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 78,000.00 |
| Dec 31, 2025 | 947,000.00 |
| Mar 31, 2025 | 1.10 Mn |
| Dec 31, 2024 | -836,000.00 |
| Jun 30, 2024 | 33.27 Mn |
| Mar 31, 2024 | 5.84 Mn |
| Dec 31, 2023 | 8.27 Mn |
| Sep 30, 2023 | 6.55 Mn |
| Jun 30, 2023 | 5.25 Mn |
| Mar 31, 2023 | 5.94 Mn |
| Dec 31, 2022 | 16.80 Mn |
| Sep 30, 2022 | 20.71 Mn |
| Jun 30, 2022 | 39.27 Mn |
| Mar 31, 2022 | 34.00 Mn |
| Dec 31, 2021 | 29.94 Mn |
| Sep 30, 2021 | 24.43 Mn |
| Jun 30, 2021 | 19.66 Mn |
| Mar 31, 2021 | 11.05 Mn |
| Dec 31, 2020 | 11.95 Mn |
| Sep 30, 2020 | 4.65 Mn |